Actylis Acquires Pharm-Rx, a Leading Value-Added Supplier of Specialty Ingredients for the Vitamin, Mineral, and Supplement and Pharmaceutical Industries
| KTRADelisted Stock | USD 6.30 0.14 2.17% |
About 62% of Kintara Therapeutics' investor base is looking to short. The analysis of current outlook of investing in Kintara Therapeutics suggests that many traders are alarmed regarding Kintara Therapeutics' prospects. The current market sentiment, together with Kintara Therapeutics' historical and current headlines, can help investors time the market. In addition, many technical investors use Kintara Therapeutics stock news signals to limit their universe of possible portfolio assets.
Kintara |
PORT WASHINGTON, N.Y., October 07, 2024--Actylis, a provider of choice for life sciences and advanced technology specialty ingredients, today announced the strategic acquisition of Pharm-Rx, a leading value-added supplier of specialty ingredients for the vitamin, mineral, and supplement and pharmaceutical industries. The Pharm-Rx acquisition significantly enhances Actylis ability to deliver exceptional value to its customers, increases its range of solutions for clients, and strengthens
Read at finance.yahoo.com
 |
Kintara Therapeutics Fundamental Analysis
We analyze Kintara Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Kintara Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Kintara Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Earnings Per Share
Earnings Per Share Comparative Analysis
Kintara Therapeutics is currently under evaluation in earnings per share category among its peers. Earnings per Share (EPS) denotes the portion of a company's earnings that is allocated to each share of common stock. To calculate Earnings per Share investors will need to take a company's net income, subtract any dividends for preferred stock, and divide it by the number of average outstanding shares. EPS is usually presented in two different ways: basic and diluted. Fully diluted Earnings per Share takes into account effects of warrants, options, and convertible securities and is generally viewed by analysts as a more accurate measure.
Kintara Therapeutics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Kintara Therapeutics stock to make a market-neutral strategy. Peer analysis of Kintara Therapeutics could also be used in its relative valuation, which is a method of valuing Kintara Therapeutics by comparing valuation metrics with similar companies.
Peers
Kintara Therapeutics Related Equities
| ONCY | Oncolytics Biotech | 2.47 | ||||
| SLRX | Salarius Pharmaceuticals | 2.08 | ||||
| SCPH | Scpharmaceuticals | 1.57 | ||||
| MCRB | Seres Therapeutics | 1.14 | ||||
| DYAI | Dyadic International | 0.62 | ||||
| LUMO | Lumos Pharma | 0.23 | ||||
| LSTA | Lisata Therapeutics | 0.00 | ||||
| MIST | Milestone Pharmaceuticals | 0.56 | ||||
| TOVX | Theriva Biologics | 0.84 | ||||
| VCNX | Vaccinex | 1.08 | ||||
| DMAC | DiaMedica Therapeutics | 1.30 | ||||
| BOLT | Bolt Biotherapeutics | 2.83 | ||||
| GOVX | GeoVax Labs | 3.40 | ||||
| SABS | SAB Biotherapeutics | 4.17 | ||||
| CLRB | Cellectar Biosciences | 9.23 | ||||
| FBRX | Forte Biosciences | 16.80 |
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the Bollinger Bands module to use Bollinger Bands indicator to analyze target price for a given investing horizon.
Other Consideration for investing in Kintara Stock
If you are still planning to invest in Kintara Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Kintara Therapeutics' history and understand the potential risks before investing.
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated |